These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15544130)

  • 41. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
    Jones PH; McKenney JM; Karalis DG; Downey J
    Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschr Med; 2008 Jun; 150(23):39. PubMed ID: 18575369
    [No Abstract]   [Full Text] [Related]  

  • 43. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
    Wenger NK; Lewis SJ; Welty FK; Herrington DM; Bittner V;
    Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia.
    Patel JV; Hughes EA
    Int J Clin Pract; 2006 Aug; 60(8):914-21. PubMed ID: 16893434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Misleading cholesterol statistics].
    Ravnskov U
    Lakartidningen; 1999 Apr; 96(16):1947, 1949. PubMed ID: 10330861
    [No Abstract]   [Full Text] [Related]  

  • 46. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
    Vaverková H
    Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.
    Barter PJ; Rye KA
    Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953
    [No Abstract]   [Full Text] [Related]  

  • 48. [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
    Klose G
    MMW Fortschr Med; 2005 Dec; 147(49-50):20. PubMed ID: 16401005
    [No Abstract]   [Full Text] [Related]  

  • 49. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
    Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
    Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances in the management of hyperlipidemia-induced atherosclerosis.
    Tannock LR
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):369-83. PubMed ID: 18327996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Simvastatin 40 mg as secondary prophylaxis: Effective, tolerable and cost-efficient!].
    Hernborg A; Hjemdahl P; Håkansson J
    Lakartidningen; 2006 Mar 15-21; 103(11):858, 861; discussion 861-2. PubMed ID: 16613120
    [No Abstract]   [Full Text] [Related]  

  • 52. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
    McKenney J; Ballantyne CM; Feldman TA; Brady WE; Shah A; Davies MJ; Palmisano J; Mitchel YB
    MedGenMed; 2005 Jul; 7(3):3. PubMed ID: 16369229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Time- and dose-dependent effect of psyllium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled clinical trials.
    Wei ZH; Wang H; Chen XY; Wang BS; Rong ZX; Wang BS; Su BH; Chen HZ
    Eur J Clin Nutr; 2009 Jul; 63(7):821-7. PubMed ID: 18985059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New trends in lipid management: eight cases to consider.
    Smith DA
    Mt Sinai J Med; 2005 Mar; 72(2):90-9. PubMed ID: 15770338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New lowdown on cholesterol. The latest advisory ratchets down targets for LDL (bad) cholesterol for some people, not others; no one-size-fits-all recommendations yet.
    Harv Heart Lett; 2004 Oct; 15(2):1-3. PubMed ID: 15496362
    [No Abstract]   [Full Text] [Related]  

  • 56. In brief: Zetia and Vytorin: the ENHANCE study.
    Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
    [No Abstract]   [Full Text] [Related]  

  • 57. Rational prescribing of statins.
    Purcell H; Daly C; Sheppard M; Morrell J
    Practitioner; 2001 Nov; 245(1628):957-9, 962-3. PubMed ID: 11727350
    [No Abstract]   [Full Text] [Related]  

  • 58. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
    Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 'Rule of 80' for coronary disease?
    Karthikeyan G; Bhargava B; Reddy KS
    Natl Med J India; 2004; 17(5):281. PubMed ID: 15638319
    [No Abstract]   [Full Text] [Related]  

  • 60. [New lower cholesterol levels--more debate].
    Lindberg M
    Ugeskr Laeger; 2005 Jan; 167(3):307-8; author reply 308-9. PubMed ID: 15704805
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.